IL126095A0 - Azolobenzazepine derivatives as neurogically active agents - Google Patents
Azolobenzazepine derivatives as neurogically active agentsInfo
- Publication number
- IL126095A0 IL126095A0 IL12609597A IL12609597A IL126095A0 IL 126095 A0 IL126095 A0 IL 126095A0 IL 12609597 A IL12609597 A IL 12609597A IL 12609597 A IL12609597 A IL 12609597A IL 126095 A0 IL126095 A0 IL 126095A0
- Authority
- IL
- Israel
- Prior art keywords
- neurogically
- azolobenzazepine
- derivatives
- active agents
- agents
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- PLKKXWBJOVTVEU-UHFFFAOYSA-N pyrrolo[2,3-i][1]benzazepine Chemical class C1=CC=NC2=C3C=CN=C3C=CC2=C1 PLKKXWBJOVTVEU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1352896P | 1996-03-08 | 1996-03-08 | |
| PCT/GB1997/000592 WO1997032883A1 (en) | 1996-03-08 | 1997-03-04 | Azolobenzazepine derivatives as neurologically active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL126095A0 true IL126095A0 (en) | 1999-05-09 |
Family
ID=21760422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12609597A IL126095A0 (en) | 1996-03-08 | 1997-03-04 | Azolobenzazepine derivatives as neurogically active agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6124281A (OSRAM) |
| EP (1) | EP0888350A1 (OSRAM) |
| JP (1) | JP2000506160A (OSRAM) |
| KR (1) | KR19990087585A (OSRAM) |
| CN (1) | CN1084747C (OSRAM) |
| AU (1) | AU723860B2 (OSRAM) |
| CA (1) | CA2247453A1 (OSRAM) |
| IL (1) | IL126095A0 (OSRAM) |
| NO (1) | NO984106L (OSRAM) |
| NZ (1) | NZ330973A (OSRAM) |
| TW (1) | TW486480B (OSRAM) |
| WO (1) | WO1997032883A1 (OSRAM) |
| ZA (1) | ZA971964B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2305307C (en) * | 1997-09-29 | 2004-11-30 | Meiji Seika Kaisha, Ltd. | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| US7919109B2 (en) * | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| CA2471651C (en) * | 2001-12-26 | 2010-01-26 | Meiji Seika Kaisha, Ltd. | Amorphous substance of tricyclic triazolobenzazepine derivative |
| BR0307504A (pt) * | 2002-02-07 | 2004-12-07 | Neurogen Corp | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| BRPI0511139B8 (pt) | 2004-05-14 | 2021-05-25 | Millennium Pharm Inc | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| NZ572003A (en) | 2006-05-30 | 2010-07-30 | Intarcia Therapeutics Inc | Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel |
| DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| PL2157967T3 (pl) | 2007-04-23 | 2013-06-28 | Intarcia Therapeutics Inc | Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN102264368B (zh) | 2008-12-22 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂与抗cd20抗体的组合 |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
| JP2013520424A (ja) | 2010-02-19 | 2013-06-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| EP3324976A4 (en) | 2015-07-21 | 2019-03-27 | Millennium Pharmaceuticals, Inc. | ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS |
| MA53353A (fr) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9311948D0 (en) * | 1993-06-10 | 1993-07-28 | Zeneca Ltd | Substituted nitrogen heterocycles |
| JP3290664B2 (ja) * | 1993-12-28 | 2002-06-10 | 明治製菓株式会社 | ３環性ベンゾアゼピンおよびベンゾチアゼピン誘導体 |
| EP0834512A4 (en) * | 1995-06-15 | 2001-08-22 | Meiji Seika Kaisha | TRICLYCLIC BENZAZEPINE COMPOUNDS. |
-
1997
- 1997-03-04 CN CN97192864A patent/CN1084747C/zh not_active Expired - Fee Related
- 1997-03-04 IL IL12609597A patent/IL126095A0/xx unknown
- 1997-03-04 CA CA002247453A patent/CA2247453A1/en not_active Abandoned
- 1997-03-04 JP JP9531562A patent/JP2000506160A/ja not_active Ceased
- 1997-03-04 TW TW086102601A patent/TW486480B/zh active
- 1997-03-04 KR KR1019980707026A patent/KR19990087585A/ko not_active Withdrawn
- 1997-03-04 WO PCT/GB1997/000592 patent/WO1997032883A1/en not_active Ceased
- 1997-03-04 AU AU22253/97A patent/AU723860B2/en not_active Ceased
- 1997-03-04 NZ NZ330973A patent/NZ330973A/xx unknown
- 1997-03-04 EP EP97905327A patent/EP0888350A1/en not_active Withdrawn
- 1997-03-04 US US09/142,221 patent/US6124281A/en not_active Expired - Fee Related
- 1997-03-06 ZA ZA9701964A patent/ZA971964B/xx unknown
-
1998
- 1998-09-07 NO NO984106A patent/NO984106L/no not_active Application Discontinuation
-
2000
- 2000-09-22 US US09/668,261 patent/US6313290B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6313290B1 (en) | 2001-11-06 |
| JP2000506160A (ja) | 2000-05-23 |
| TW486480B (en) | 2002-05-11 |
| NO984106L (no) | 1998-11-06 |
| US6124281A (en) | 2000-09-26 |
| KR19990087585A (ko) | 1999-12-27 |
| CN1224424A (zh) | 1999-07-28 |
| WO1997032883A1 (en) | 1997-09-12 |
| EP0888350A1 (en) | 1999-01-07 |
| CA2247453A1 (en) | 1997-09-12 |
| NO984106D0 (no) | 1998-09-07 |
| CN1084747C (zh) | 2002-05-15 |
| AU723860B2 (en) | 2000-09-07 |
| ZA971964B (en) | 1997-09-08 |
| NZ330973A (en) | 2000-03-27 |
| AU2225397A (en) | 1997-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL126095A0 (en) | Azolobenzazepine derivatives as neurogically active agents | |
| EG24081A (en) | 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives | |
| GB9510757D0 (en) | Therapeuticaly active compounds | |
| HUP0003642A3 (en) | N-alkanoylphenylalanine derivatives | |
| GB9702194D0 (en) | Sulphonide derivatives | |
| HUP0000575A3 (en) | Novel formulation comprising budesonid as active indegredient | |
| HUP0100870A3 (en) | Alpha-aminoamide derivatives useful as analgesic agents | |
| HUP9801168A3 (en) | Triazinylaminostilbene derivatives | |
| GB2321457B (en) | 5-Aroylnaphthalene derivatives | |
| IL132982A0 (en) | Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives | |
| GB9715821D0 (en) | Amidino-camptothecin derivatives | |
| GB9725541D0 (en) | Amino-benzothiazole derivatives | |
| AU2361295A (en) | N-carboxyalkyl derivatives as antidegenerative active agents | |
| GB9701628D0 (en) | Imino-aza-anthracyclinone derivatives | |
| GB9603431D0 (en) | Immunodulating active substance | |
| EP0910356A4 (en) | BIPHENYLAMIDO DERIVATIVES AS MELATONERGIC AGENTS | |
| ZA983116B (en) | Arylsecocholadiene derivatives | |
| AP9901651A0 (en) | Nitro-benzamide useful as anti-arrhytmic agent | |
| IL131159A0 (en) | 4-Aminoethoxyindazole derivatives | |
| GB9706753D0 (en) | Aralkoxy-morphinan derivatives | |
| SI1005445T1 (en) | N-alkanoylphenylalanine derivatives | |
| GB9608678D0 (en) | Pharmaceuticlly active compounds | |
| PL316604A1 (en) | Active self-extinguising line | |
| GB9709884D0 (en) | Pharmacoligically active compounds | |
| HK1016901A (en) | Biphenylamido derivatives as melatonergic agents |